From 2007.igem.org

• Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins.
  Science,1982,215(5):687-688.
• Secretion of heterologous gene products to the culture medium of Escherichia coli.
  Nucleic Acids Res. 1986 Sep 25;14(18):7487-500.
• Engineering Escherichia coli to secrete heterologous gene products.
  Methods Enzymol. 1990;185:166-187.
• <a href="http://www.patentstorm.us/patents/5460954-claims.html">Production of human proinsulin using a novel vector system</a>. (patent)
  United States Patent 5460954 Issued on October 24, 1995.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=8840785&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Strategies for achieving high-level expression of genes in Escherichia coli.</a>
  Microbiol Rev. 1996 Sep;60(3):512-538.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10508629&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Recombinant protein expression in Escherichia coli</a>.
  Curr Opin Biotechnol. 1999 Oct;10(5):411-421. 
• Advances in Escherichia coli production of therapeutic proteins.
  Curr Opin Biotechnol. 2001 Apr;12(2):195-201.
• <a href="http://www3.interscience.wiley.com/cgi-bin/abstract/107623865/ABSTRACT?CRETRY=1&SRETRY=0">Enhancement of recombinant protein synthesis and stability via coordinated amino acid addition</a>.
  Biotechnology and Bioengineering, Volume 41, Issue 5 , Pages 557 - 565, 2004.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15286986&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">Growth-rate recovery of Escherichia coli cultures carrying a multicopy plasmid, 
  by engineering of the pentose-phosphate pathway.</a>
  Biotechnol Bioeng. 2004 Aug 20;87(4):485-494.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15480623&ordinalpos=39&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">Recombinant expression systems in the pharmaceutical industry.</a>
  Appl Microbiol Biotechnol. 2004 Sep;65(4):363-372.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15598350&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Production of soluble mammalian proteins in Escherichia coli: 
  identification of protein features that correlate with successful expression.</a>
  BMC Biotechnol. 2004 Dec 14;4:32.
• Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli.
  Microb Cell Fact. 2005 Jan 4;4(1):1. 
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15607230&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Advanced genetic strategies for recombinant protein expression in Escherichia coli.</a>
  J Biotechnol. 2005 Jan 26;115(2):113-128.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15691914&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Improved secretory production of recombinant proteins by random mutagenesis of hlyB, 
  an alpha-hemolysin transporter from Escherichia coli.</a>
  Appl Environ Microbiol. 2005 Feb;71(2):656-662.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15848232&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Highly efficient protein expression and purification using bacterial hemoglobin fusion vector</a>.
  Plasmid. 2005 May;53(3):274-82. 
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15635462&ordinalpos=35&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">Strategies for efficient production of heterologous proteins in Escherichia coli</a>.
  Appl Microbiol Biotechnol. 2005 May;67(3):289-298.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16472168&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Expression of highly toxic genes in E. coli: special strategies and genetic tools</a>.
  Curr Protein Pept Sci. 2006 Feb;7(1):47-56.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15580578&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Engineering HlyA hypersecretion in Escherichia coli based on proteomic and microarray analyses</a>.
  Biotechnol Bioeng. 2005 Jan 20;89(2):195-205.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16781139&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Enhancement of soluble protein expression through the use of fusion tags.</a>
  Curr Opin Biotechnol. 2006 Aug;17(4):353-358.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16146696&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Enhanced soluble protein expression using two new fusion tags.</a>
  Protein Expr Purif. 2006 Mar;46(1):122-129.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16509985&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production.</a>
  BMC Biotechnol. 2006 Mar 1;6:12.
• <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17275326&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus">Expression of membrane proteins from Mycobacterium tuberculosis in Escherichia coli as fusions with maltose binding protein</a>.
  Protein Expr Purif. 2007 May;53(1):24-30.